平消胶囊对手术后Ⅰ～Ⅱa期非小细胞肺癌的治疗分析临床医学.docVIP

平消胶囊对手术后Ⅰ～Ⅱa期非小细胞肺癌的治疗分析临床医学 目录 TOC \o 1-9 \h \z \u 目录 1 正文 1 文1：平消胶囊对手术后Ⅰ～Ⅱa期非小细胞肺癌的治疗分析临床医学 1 1 资料和方法 3 3 讨论 4 文2：非小细胞肺癌的治疗进展临床医学 5 1 手术治疗 5 2 化疗 7 3 放疗 8 4 中西医结合治疗 9 5 分子靶向药物治疗 10 6 介入疗法 11 7 免疫治疗 12 8 基因 治疗 13 参考文摘引言： 13 原创性声明（模板） 14 文章致谢（模板） 15 正文 平消胶囊对手术后Ⅰ～Ⅱa期非小细胞肺癌的治疗分析临床医学 文1：平消胶囊对手术后Ⅰ～Ⅱa期非小细胞肺癌的治疗分析临床医学 【ABSTRACT】 Objective: To investigate the survival rate in one and three yea,the immunity and living quality while the Ⅰ～Ⅱa CLC patients were treated with Pingxiao Capsule after :The patients confirmed suffering from non small cell lung cancer（CLC） were diagnosed being in the Ⅰ～Ⅱa period,Karnofsky≥70,35~70 yea old (including 35 and 75).The group was treated with Pingxiao Capsule,4~5 capsules pertime,three times a day,taking 90 days as treating coue,but the control group didnt receive any the treatment ended,the survival rate, immunity and living quality were :For the treated group,the survival rates for one and three yea were 955% and 665% the control group,the rates of that were 940% and 645%.There is no significant differece between the two groups（P005）.The specific data of outside Tcell submass and limphcell in the treated group was higher than that of the control group（P005）.The treated groups living quality(living quality form of questionnaire,weight,calculative mark) was higher than that of the control group（P005）.Conclusion:Pingxiao Capsule has the function to improve patients immunity and living there is no remarkable affect on survival rate of the patients suffering from nomall cell lung cancer after operation. 【KEY WORDS】 Pingxiao Capsule;Ⅰ～Ⅱa CLC 手术治疗是Ⅰ～Ⅱa期非小细胞肺癌的主要治疗手段，对Ⅰ～Ⅱa期非小细胞肺癌是否常规进行化学治疗存在争议，中西医结合是我国肿瘤治疗的特色和优势。鉴于人们普遍存在的对化疗的恐惧感和对中药的易顺从性，我们于2000～2003年对30例经手术证实的Ⅰ～Ⅱa期非小细胞肺癌应用平消胶囊治疗，并进行对照，发现其增加患者免疫力及提高生存质量的作用较明显，但对术后Ⅰ～Ⅱa期非小细胞肺癌的１、３年生存率无明显影响，现分析报告如下。 1 资料和方法 11 一般资料 我们于2000～2003年对60例经手术证实的Ⅰ～Ⅱa期非小细胞肺癌，随机分为手术加平消胶囊组（下称治疗组）和对照组。治疗组30例，男22例，女8例；年龄32～72岁（中位年龄57岁）；鳞癌20例，腺癌9例，腺鳞癌1例。对照组例，男18例，女12例；年龄38～75岁